anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cervical cancer is the third most common gynecological cancer worldwide. Its origin is linked to intraepithelial lesions caused by high-risk Human Papillomavirus (HPV) types, detected in 99.7% of cases. Early screening is essential to prevent cancer development from these lesions. Molecular methods are more specific and offer the possibility of being performed through a self-collected sample by the patient, thus contributing to increasing screening coverage for this pathology. This study aim was to map the medical-scientific literature on existing protocols for self-sampling for HPV testing in cervical cancer screening. A search strategy was developed using the following keywords and their synonyms: "self-sampling," "professional sampling," and "HPV", on the databases: MEDLINE, Cochrane Library, Virtual Health Library - BVS, Scopus, National Institute for Health Research NHS EED, Web of Science, and EMBASE. The search strategy was formulated to identify relevant studies and describe their main characteristics, such as patient acceptance of self-sampling, cost differences between the tests used, and the accuracy of self-sampling compared to the gold standard test. A total of 876 studies were found, and 33 of those studies were included in this review. Out of these, 10 studies were domized clinical trials involving 46,751 patients, and 23 observational studies included 142,795 patients. Regarding acceptance, most studies reported a preference for self-sampling. Sensitivity analyses from various studies also showed that the low cost of self-sampling kits generally increased cost-effectiveness. The study concluded that using HPV testing on self-collected samples is a viable strategy for monitoring women with HPV.
The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
Chronic venous insufficiency is one of the most common medical diseases in adults, which severely affects the quality of life of affected patients. What causes symptoms in this disease is the reflux of blood through incompetent valves located in the lower extremity veins. The most common cause is saphenofemoral valve insufficiency.

Although the pathway of reflux transmission is not the same in all patients, the removal of the greater saphenous vein (GSV) is considered a standard treatment according to the guidelines. This treatment leads to unnecessary destruction of the great saphenous vein and failure to correct the pathology in patients whose reflux exited the GSV along its transmission pathway. According to this issue, in this study, the investigators intend to investigate the different pathways of reflux transmission in chronic venous insufficiency patients who are candidates for GSV ablation/stripping because of saphenofemoral junction insufficiency according to the ultrasonographic exam. This cross-sectional study will be conducted with a descriptive-analytical approach on approximately 50 participants. Before surgery, patients are subjected to ultrasonographic mapping to check the pathway of reflux transmission and their related information is recorded. Other demographic information will also be recorded in the relevant checklist. Finally, the data will be analyzed in SPSS software.
The vital pathological processes in intimal hyperplasia include aberrant vascular smooth muscle cells (VSMCs) proliferation, migration, and phenotypic switching. Rosmarinic acid (RA) is a natural phenolic acid compound. Nevertheless, the underlying mechanism of RA in neointimal hyperplasia is still unclear. Our analysis illustrated that miR-25-3p mimics significantly enhanced PDGF-BB-mediated VSMCs proliferation, migration, and phenotypic switching while RA partially weakened the effect of miR-25-3p. Mechanistically, we found that miR-25-3p directly targets sirtuin (SIRT6). The suppressive effect of the miR-25-3p inhibitor on PDGF-BB-induced VSMCs proliferation, migration, and phenotypic switch was partially eliminated by SIRT6 knockdown. The suppression of the PDGF-BB-stimulated Nrf2/ARE signaling pathway that was activated by the miR-25-3p inhibitor was exacerbated by the SIRT6 knockdown. In in vivo experiments, RA reduced the degree of intimal hyperplasia while miR-25-3p agomir partially reversed the suppressive effect of RA in vascular remodeling. Our results indicate that RA activates the Nrf2/ARE signaling pathway via the miR-25-3p/SIRT6 axis to inhibit vascular remodeling.
Participants with untreated DLBCL will receive Pola-R-CHP + glofitamab on Day 1 of each 21-day cycle for a maximum of 6 cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
PURPOSE: To obtain a new erythropoietin compound having high in vivo bioactivity and useful for the therapy and/or prophylaxis of anemia, or the like, of chronic renal failure patients. CONSTITUTION: This new erythropoietin compound is a complex containing an erythropoietin glyco-protein having at least one free amino group, having an in vivo bioactivity increasing the production of reticullocyte, or the like, in myeloid cells and selected from human erythropoietin, or the like. The above glyco-protein is combined through a covalent bond with an 'n' polyethylene glycol group of the formula CO-(CH2)x-(OCH2CH2)m-OR (R is a lower alkyl; X is 2 or 3; (m) is about 450-900 and (n) is 1 to 3 with the proviso that (m) and (n) are selected in such a way that a difference in mol.wt. between the complex and the erythropoietin glyco-protein is 20-100 kDa). CO of each polyethylene glycol group is combined with one of amino groups mentioned above to form an amide linkage in the complex. The new compound is obtained by the condensation reaction of a compound of the formula with the erythropoietin glyco-protein.
Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
This cross-sectional study was conducted at the Faculty of Physiotherapy and Rehabilitation, University of Health Sciences. All evaluations were performed in the university physiotherapy laboratories. All of the participants were informed about the study and provided written informed consent. This study was performed in accordance with the 1964 Helsinki declaration, its later amendments.110 people over the age of 18 were included in the study. Posture-oriented exercises were applied online 3 times a week for 12 weeks. Postural measurements, performance, and energy consumption levels were determined for each participant before and after the intervention. Craniovertebral angle and shoulder angle were measured with a smartphone application and muscle shortness was measured with clinical tests among postural measurements. Performance measurement was evaluated with the 6-minute walking test, and energy consumption was evaluated with the Physiological Cost Index. Individuals diagnosed with mechanical neck pain who applied to the university's wellness center for exercise between September 2021 and December 2021 were determined by physiotherapists who are experts in their fields. A cross-sectional selection of 110 individuals met the inclusion criteria. This study was conducted with assessments made before and after posture-based telerehabilitation.
Ringer's lactate solution, or lactated Ringer's solution, is a type of isotonic, crystalloid fluid further classified as a balanced or buffered solution used for fluid replacement. The contents of Ringer's lactate include sodium, chloride, potassium, calcium, and lactate in the form of sodium lactate, mixed into a solution with an osmolarity of 273 mOsm/L and pH of about 6.5.
The present invention describes a novel intervention strategy for the treatment of dysregulated inflammations by using hepatic acute phase proteins serum amyloid A (SAA), CXCL-1/GRO-1/KC or C-reactive protein (CRP) or neutralizing antibodies to these proteins as diseases modulators. The said proteins are to be used as pharmaceutical compositions in the treatment of conditions and diseases characterized by dysregulated inflammations. Besides direct anti-inflammatory as well as host-defensive effects, a hitherto unrecognized regulation of myeloid-derived suppressor cells (MDSC) is uncovered. Myeloid derived suppressor cells seem to be key regulators of inflammatory responses during sepsis and thus represent a valuable target for treatment of these disorders. In a further aspect, the present invention concerns the use of effective amounts of the above identified active agents for activation and mobilisation of MDSC for treatment of excessive dysregulated inflammatory diseases. Further the use of neutralizing antibodies or small molecular inhibitors to treat conditions of suppressed inflammatory responses such as cancer is claimed. The present invention proposes the use of blocking antibodies to SAA, CXCL-1/GRO-1/KC and CRP to prevent MDSC activity and thus boost anti-tumor immune responses in cancer.
Red blood cell (RBC) transfusion is a critical therapy for those with sickle cell disease (SCD). Alloimmunization is frequent for those with SCD and may limit the availability of matched RBC. Cryopreserved RBCs, from family members or donors with a similar RBC antigen profile could provide a viable alternative to avoid further alloimmunization and prevent hemolytic transfusion-related events. However, cryopreserved SCD and Sickle Cell trait (S-trait) donor RBC units suffer from reduced recovery following deglycerolization. This study proposes and tests a modified deglycerolization protocol using an automated cell processor to mitigate RBC loss. Six red cell concentrates (RCC) from donors with S-trait and six control RCCs were glycerolized, frozen (<-65 °C) and deglycerolized on the ACP 215 using modified parameters (decreased hypertonic solution flow rate (100 mL/min) and hypertonic equilibration delay (120 s), and increased NaCl dilution volumes (500 mL). Quality testing included: hematocrit (HCT), hemolysis, indices, extracellular potassium, morphology, osmotic fragility, osmotic gradient ektacytometry, hemoglobin (HGB), and recovery. Canadian standards (CS) indicate that acceptable deglycerolized units for transfusion require a HCT ≤0.80 L/L, HGB ≥35 g/unit, and hemolysis <0.8 % in 90 % of units tested. No significant differences in HGB or RBC recovery were observed between study groups. Significant differences between study groups were identified in osmotic fragility and osmotic gradient ektacytometry parameters. Of the 6 S-trait RCCs, 3/6 units were within the HCT, HGB and hemolysis thresholds set by the CS. The modified deglycerolization protocol provides a path for the routine cryopreservation of S-trait RBCs.
Received the same mindfulness therapy training audio as the other set, but did not watch the 3D scene on the VR device. At the end of the study, we will compensate them and let them use VR for relaxation training according to their wishes.
PURPOSE: To obtain a cosmetic, excellent in vehicular properties and having a high chromaticness and a beautiful coated color by blending a particulate iron oxide, prepared by a vapor process for weakening the cohesion among particles, having a specific average primary particle diameter and excellent in dispersibility therein. CONSTITUTION: This cosmetic is obtained by blending a particulate iron oxide, produced by a vapor process, e.g. decomposition of pentacarbonyliron and having an average primary particle diameter within the range of 1-10nm and a spherical or an irregular shape therein. An organopolysiloxane is further preferably blended in the resultant system. Red iron oxide is preferred as the particulate iron oxide. A polyoxyalkylene-modified polysiloxane, a perfluoroalkyl- polyoxyalkylene-comodified polysiloxane and a perfluoroalkyl-modified polysiloxane are preferred as the organopolysiloxane. The amount of the particulate iron oxide is preferably about 0.1-15 pts.wt. based on 100 pts.wt. cosmetic. A face powder, a foundation, a pressed powder, a foundation using water, etc., are cited as the cosmetic.
This study investigated the effects of substituting inorganic trace minerals (ITM) with advanced chelate technology-based TM (ACTM) in broiler chicken feed on productive performance, metabolic profile, humoral immunity, antioxidant status, and modulation of NF-kB and Nrf2 signaling pathways in mixed Eimeria species exposure. The study involved 480 newly hatched male broiler chickens, which were divided into 5 treatment groups, each with 6 replicate cages and 16 chickens per replicate. The experimental treatments included an uninfected negative control group fed a basal diet with recommended inorganic TM levels (NC), an infected positive control group fed the same diet (PC), a PC group supplemented with salinomycin (SAL), and two PC groups in which the basal diet was replaced with 50% and 100% ACTM instead of inorganic TM (ACTM50 and ACTM100, respectively). All groups, except for the NC group, were orally challenged with mixed Eimeria species oocysts on day 14. According to the results, the PC group showed lower feed intake, breast yield, low-density lipoprotein-cholesterol concentration, lactobacillus spp. counts, and serum IgG levels, but higher jejunal TGF-β expression versus the NC group. The broilers in the NC, SAL, and ACTM100 groups showed higher body weight gain, carcass yield, and TGF-β expression, but lower serum alkaline phosphatase activity, ileal E. coli count, and jejunal expression levels of IL-1β, IL-6, IFN-γ, Nrf2, and SOD1 compared to the PC group, with the NC group having the highest body weight gain and lowest IL-1β and Nrf2 expression levels. Furthermore, the administration of ACTM100 treatment improved feed efficiency, increased serum iron, zinc, manganese, and copper levels, enhanced total antioxidant capacity and different antioxidant enzyme activities, and reduced malondialdehyde concentration. In conclusion, complete replacement of ITM with ACTM effectively protects broilers from Eimeria infection, with similar positive effects to SAL treatment in terms of productive performance and anti-inflammatory responses and better antioxidant responses and mineral availability.
Based on its mechanism of action and findings in animal studies, lapatinib tablets can cause fetal harm when administered to a pregnant woman. In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. When administered to pregnant animals during the period of organogenesis, lapatinib caused fetal anomalies (rats) or abortions (rabbits) at maternally toxic doses (with maternal exposures approximately 6.4 and 0.2 times, respectively, the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine).

  


Advise pregnant women and females of reproductive potential of the potential risk to the fetus [see Use in Specific Populations (8.1) and Clinical Pharmacology (12.1)]. Verify the pregnancy status of females of reproductive potential prior to initiation of lapatinib tablets. Advise females of reproductive potential to use effective contraception during treatment with lapatinib tablets and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with lapatinib tablets and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)].
BACKGROUND: Postoperative pancreatic fistula (POPF) is the most prevalent complications following minimally invasive pancreaticoduodenectomy (MIPD). Only one model related to MIPD exists, and previous POPF scoring prediction methods are based on open pancreaticoduodenectomy patients. Our objectives are to determine the variables that may increase the probability of pancreatic fistula following MIPD and to develop and validate a POPF predictive risk model.
METHODS: Data from 432 patients who underwent MIPD between July 2015 and May 2022 were retrospectively collected. A nomogram prediction model was created using multivariate logistic regression analysis to evaluate independent factors for POPF in patients undergoing MIPD in the modeling cohort. The area under the curve (AUC) of the receiver operating characteristic curve (ROC) and the calibration curve were used to verify the nomogram prediction model internally and externally within the modeling cohort and the verification cohort.
RESULTS: Multivariate logistic regression analysis showed that body mass index (BMI), albumin, triglycerides, pancreatic duct diameter, pathological diagnosis and intraoperative bleeding were independent variables for POPF. On the basis of this information, a model for the prediction of risks associated with POPF was developed. In accordance with the ROC analysis, the modeling cohort's AUC was 0.819 (95% CI 0.747-0.891), the internal validation cohort's AUC was 0.830 (95% CI 0.747-0.912), and the external validation cohort's AUC was 0.793 (95% CI 0.671-0.915). Based on the calibration curve, the estimated values of POPF have a high degree of concordance with the actual values that were measured.
CONCLUSIONS: This model for predicting the probability of pancreatic fistula following MIPD has strong predictive capacity and can provide a trustworthy predictive method for the early screening of high-risk patients with pancreatic fistula after MIPD and timely clinical intervention.
Understanding the association between compliance to the Chronic Kidney Disease (CKD) guidelines in real-world clinical settings and renal outcomes remains a critical gap in knowledge. A comprehensive analysis was conducted using data from a national, multicenter CKD registry. This study included 4,455 patients with an estimated glomerular filtration rate (eGFR) measurement on the index date and eight additional metrics recorded within six months. These metrics comprised serum electrolyte levels, low-density lipoprotein cholesterol, hemoglobin, and the use of renin-angiotensin system inhibitors. The primary outcome was a composite of renal events, defined by a decline in eGFR to < 15 mL/min/1.73 m2 or a reduction of ≥ 30% in eGFR, confirmed by follow-up tests. Over a median follow-up of 513 days, 838 renal events were observed. High serum potassium levels (> 5.4 mmol/L) were associated with increased event rates compared to lower levels. Similarly, low serum sodium-chloride levels (< 33) correlated with higher event rates. Usage of renin-angiotensin system inhibitors, low serum calcium (< 8.4 mg/dL), and high uric acid levels (> 7.0 mg/dL) were also linked to increased events. Conversely, higher hemoglobin levels (≥ 13 g/dL) were associated with lower event rates. Compliance to guidelines, categorized into quartiles based on the number of met metrics, revealed a significantly reduced risk of events in the highest compliance group (meeting 8 metrics) compared to the lowest (0-5 metrics). Compliance to CKD guidelines in clinical practice is significantly associated with improved renal outcomes, emphasizing the need for guideline-concordant care in the management of CKD.
PURPOSE: To obtain an pharmaceutical composition comprising a therapeutically effective amount of glycine B partial agonist or its prodrug thereof as an active ingredient and useful for treating mental diseases. CONSTITUTION: This pharmaceutical composition comprises a therapeutically effective amount of compound or its prodrug thereof as an active ingredient. One or more compounds selected from a compound group of the formula (R<1> is a hydrido, an alkyl, a haloalkyl, etc.; R<2> is a hydrido, an alkyl, aralkyl, etc.; R<3> is a hydrido, an alkyl, a haloalkyl, an alkoxy, etc.) or its salt is used as the compound. The composition has possibility to treatment for acute or chronic phencyclidine (general anesthetic)-induced psychiatric disorder.
PURPOSE: A novel Bacillus amyloliquefaciens CS61 culture is provided to ensure excellent antibacterial function, DPPH radical removal ability, and high reducing ability. CONSTITUTION: An antioxidant contains Bacillus amyloliquefaciens CS61(KCTC 11901BP) culture as an active ingredient. An anti-inflammatory agent contains the cutlure as an active ingredient. A pharmaceutical composition for suppressing the growth of antibiotic resistant pathogenic microorganism or enteric harmful microorganism contains the culture as an active ingredient. The antibiotic resistant pathogenic microorganism is Methicillin Resistant Staphylococcus aureus(MRSA) or vancomycin resistant enterococcus(VRE). The enteric harmful microorganism is E.coli, Staphylococcus aurues, Enterococcus, or Salmonella.
PURPOSE: A base, a nucleoside, or a nucleotide effectively is provided to suppress virus replication with less side effects and to be used as an antiviral pharmaceutical composition. CONSTITUTION: An antiviral pharmaceutical composition contains one or more selected from the group consisting of adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, adenosine biphosphate, and adenosine triphosphate. Rhinovirus is selected among rhinovirus type 2, 3, 14, 15, and 40. Enterovirus is enterovirus type 71. A pharmaceutical composition for anti-influenza virus contains adenosine and/or adenine as active ingredients. The influenza virus is influenza virus type A.
BACKGROUND: Amiodarone (AMIO) is an antiarrhythmic drug with the pKa in the physiological range. Here, we explored how mild extracellular pH (pHe) changes shape the interaction of AMIO with atrial tissue and impact its pharmacological properties in the classical model of sea anemone sodium channel neurotoxin type 2 (ATX) induced late sodium current (INa-Late) and arrhythmias.
METHOD: Isolated atrial cardiomyocytes from male Wistar rats and human embryonic kidney cells expressing SCN5A Na+ channels were used for patch-clamp experiments. Isolated right atria (RA) and left atria (LA) tissue were used for bath organ experiments.
RESULTS: A more acidophilic pHe caused negative inotropic effects on isolated RA and LA atrial tissue, without modification of the pharmacological properties of AMIO. A pHe of 7.0 changed the sodium current (INa) related components of the action potential (AP), which was enhanced in the presence of AMIO. ATXinduced arrhythmias in isolated RA and LA. Also, ATX prolonged the AP duration and enhanced repolarization dispersion in isolated cardiomyocytes in both pHe 7.4 and pHe 7.0. Pre-incubation of the isolated RA and LA and isolated atrial cardiomyocytes with AMIO prevented arrhythmias induced by ATX only at a pHe of 7.0. Moreover, AMIO was able to block INa-Late induced by ATX only at a pHe of 7.0.
CONCLUSION: The pharmacological properties of AMIO concerning healthy rat atrial tissue are not dependent on pHe. However, the prevention of arrhythmias induced by INa-Late is pHe-dependent. The development of drugs analogous to AMIO with charge stabilization may help to create more effective drugs to treat arrhythmias related to the INa-Late.